Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

Capacity Expansion:
Samsung Biologics is set to open Bio Campus II with Plant 5 in April 2025, increasing its total biomanufacturing capacity to 784,000 liters. Plans for a sixth plant are under consideration, which would further increase capacity to 964,000 liters upon board approval12.

ADC Services:
The company has commenced ADC services at its new dedicated facility, leveraging its expertise in large-scale antibody manufacturing and process engineering to support late-stage discovery, development, and conjugation12.

Digital Transformation:
Samsung Biologics is investing in integrated digital systems, incorporating artificial intelligence and digital twin technology, to enhance operational efficiency and client satisfaction12.

Growth Strategy:
The company aims to address growing demand for biologics and ADC-based therapeutics by expanding its capabilities and investing in new modalities and technologies12.

Client Base:
Samsung Biologics has secured orders from 16 of the world's top 20 pharmaceutical companies by market capitalization, benefiting from its top-notch manufacturing capabilities and the ongoing US-China trade row4.

Future Plans:
The company plans to build more plants in phases, with the sixth one by 2027 and the seventh and eighth ones by 2032, aiming to reach a combined capacity of 1.3 million liters3.

Sources:

1. https://samsungbiologics.com/media/company-news/samsung-biologics-2025-jp-morgan-healthcare-conference

2. https://www.prnewswire.com/news-releases/samsung-biologics-presents-business-updates-at-2025-jp-morgan-healthcare-conference-302351137.html

3. https://www.koreaherald.com/view.php?ud=20231018000713

4. https://www.kedglobal.com/bio-pharma/newsView/ked202406070004